logo
logo
Search stocks & features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
ScreenersScreeners
MoreMore

prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
EMA ScreenerEMA Screener
SMA ScreenerSMA Screener
WMA ScreenerWMA Screener
OHLC ScreenerOHLC Screener
Fibonacci ScreenerFibonacci Screener
VWAP ScreenerVWAP Screener
Pivot Point ScreenerPivot Point Screener
Overlay ScreenerOverlay Screener
Trend Indicator ScreenerTrend Indicator Screener
Volume Based Indicator ScreenerVolume Based Indicator Screener
Overbought/Sold ScreenerOverbought/Sold Screener
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Precious Metals
Gold Price TodayGold Price TodayNew
Silver Price TodaySilver Price TodayNew
Platinum Price TodayPlatinum Price TodayNew
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Sector BoosterSector Booster
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
IPO CalendarIPO Calendar
Economic CalendarEconomic Calendar
Market closedRefreshes 15s
Kopran

Kopran

NSE: KOPRANBSE 524280Health CarePharmaceuticalswww.kopran.com
View MapTV Chart
206.27
12.69+6.56%
DAY194
₹206.27
219
52W107
₹206.27
219
Open194.50
Prev Close193.58
Bid206.251.5K
Ask206.30964
Volume3.9M+136%vs 20D avg
Market Cap₹876.34 Cr
Promoter Hold.44.4%
Face Value₹10
Fwd P/E
PEG
EV/EBITDA36.13
P/S1.03
ROA4.57%
Beta1.42
Div Payout195.87%
Valuation

Kopran Ltd valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for Kopran Ltd, framed against the sector median so the premium or discount is obvious at a glance.

Kopran Ltd trades at a P/E of 38.72× and P/B of 1.28×.

Key MetricsLive · as of 29 May 2026
the price tag

Valuation

Market Cap
₹876.34 Cr
P/E Ratio
avg38.72
P/B Ratio
good1.68
EPS
3.41
the engine

Profitability

ROE
watch-0.05%
ROCE
watch9.75%
Net Margin
watch2.67%
Op Margin
watch6.19%
the trajectory

Growth

EPS YoY
watch-71.88%
Revenue YoY
watch-3.66%
Qtr Sales
watch-3.03%
Qtr Profit
watch-32.9%
the balance sheet

Financial Health

Debt / Equity
good0.29
Book Value
107.35
Div Yield
good2.26%
Promoter Hold.
avg44.4%
Financials

Kopran Ltd financials: P&L, balance sheet, cash flow, ratios.

Twelve years of audited numbers for Kopran Ltd, switchable between annual and quarterly views, consolidated or standalone.

Kopran Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹876.34 Cr and reported EPS of ₹3.41.

all values in ₹ Cr unless suffixed · source: company filings
Segment Analysis

Kopran segment analysis: revenue and profit mix.

Disclosed business segments at Kopran with their share of revenue and profit, switchable between consolidated and standalone reporting.

Kopran discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Investment Thesis

Kopran Ltd investment thesis: bull case, bear case, and the flip lines.

Why someone would buy Kopran Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.

Kopran Ltd's investment case rests on 7 positive markers and 9 flagged concerns drawn from the latest reported filings.

bull case

What you're getting.

  • Kopran Ltd exhibits a relatively low debt-to-equity ratio of 0.29, suggesting a manageable debt burden and a strong financial foundation for future growth and investment opportunities. This indicates a healthy balance sheet.

  • Despite recent quarterly profit variability, Kopran's promoter holding remains consistently high at approximately 44%, demonstrating significant confidence in the company's long-term prospects and potential for future value appreciation.

  • The company shows a positive return on equity (ROE) of 7.64%, indicating that Kopran Ltd is efficiently utilizing shareholder investments to generate profits. This is a key indicator of profitability and efficiency.

  • Kopran's operating profit margin (OPM) stands at a healthy 10.50%, suggesting efficient cost management and strong pricing power within its pharmaceutical industry. This demonstrates operational strength.

  • The pharmaceutical industry, where Kopran operates, is experiencing robust growth driven by increasing global healthcare expenditure and an aging population, presenting significant market expansion opportunities.

bear case

What can break it.

  • Kopran Ltd's quarterly profit has shown significant volatility, with a substantial -32.90% decrease in the most recent quarter. This needs further investigation to understand the underlying causes and potential future impact.

  • The recent stock price has experienced considerable fluctuation, falling from a 52-week high of ₹327 to a low of ₹154. This volatility presents a risk for investors seeking stability in their portfolios.

  • Kopran's relatively low Return on Capital Employed (ROCE) of 9.75% suggests that the company might not be utilizing its capital as efficiently as some of its competitors in the pharmaceutical sector. This warrants further analysis.

  • The company reported a quarterly sales decline of -3.03%, indicating potential challenges in revenue generation and market demand. This trend requires close monitoring for sustained performance.

  • The Price-to-Earnings (PE) ratio of 22.90, while not excessively high, warrants comparison to industry peers to accurately assess if it reflects the company's growth potential and future earnings.

flip conditions

What would change my mind.

  • Trim if P/E re-rates above 50. The valuation cushion thins from there.

  • Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.

  • Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.

  • Income thesis breaks if the dividend is cut or yield falls below 1.13%.

Shareholding

Kopran shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in Kopran — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Loading shareholding data...

Peers

Kopran Ltd peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Kopran Ltd is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.29L ₹ Cr
Best Profit Growth
Biofil Chemicals & Pharmaceuticals Ltd
1318.00 %
Highest Dividend Yield
Procter & Gamble Health Ltd
3.64 %

Peer Comparison

Company Name
AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd
AARTIDRUGS
Aarti Drugs Ltd
AARTIPHARM
Aarti Pharmalabs Ltd
AJANTPHARM
Ajanta Pharma Ltd
AKUMS
Akums Drugs & Pharmaceuticals Ltd
ALBERTDAVD
Albert David Ltd
ALIVUS
Alivus Life Sciences Ltd
ALKEM
Alkem Laboratories Ltd
ALPA
Alpa Laboratories Ltd
AMRUTANJAN
Amrutanjan Health Care Ltd
APLLTD
Alembic Pharmaceuticals Ltd
ASTRAZEN
Astrazeneca Pharma India Ltd
AUROPHARMA
Aurobindo Pharma Ltd
BAFNAPH
Bafna Pharmaceuticals Ltd
BAJAJHCARE
Bajaj Healthcare Ltd
BALPHARMA
Bal Pharma Ltd
BIOCON
Biocon Ltd
BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd
BLISSGVS
Bliss GVS Pharma Ltd
BLUEJET
Blue Jet Healthcare Ltd
BROOKS
Brooks Laboratories Ltd
CAPLIPOINT
Caplin Point Laboratories Ltd
CIPLA
Cipla Ltd
COHANCE
Cohance Lifesciences Ltd
CONCORDBIO
Concord Biotech Ltd
DCAL
Dishman Carbogen Amcis Ltd
DIVISLAB
Divis Laboratories Ltd
DRREDDY
Dr Reddys Laboratories Ltd
EMCURE
Emcure Pharmaceuticals Ltd
ERIS
ERIS Lifesciences Ltd
FDC
FDC Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
GRANULES
Granules India Ltd
GUFICBIO
Gufic BioSciences Ltd
HALEOSLABS
Haleos Labs Limited
HESTERBIO
Hester Biosciences Ltd
HIKAL
Hikal Ltd
INDOCO
Indoco Remedies Ltd
INDSWFTLAB
Ind-Swift Laboratories Ltd
INNOVACAP
Innova Captab Ltd
IOLCP
IOL Chemicals & Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
JUBLPHARMA
Jubilant Pharmova Ltd
KILITCH
Kilitch Drugs (India) Ltd
KOPRAN
Kopran LtdCurrent Stock
KREBSBIO
Krebs Biochemicals & Industries Ltd
LASA
Lasa Supergenerics Ltd
LAURUSLABS
Laurus Labs Ltd
LINCOLN
Lincoln Pharmaceuticals Ltd
LUPIN
Lupin Ltd
LYKALABS
Lyka Labs Ltd
MANGALAM
Mangalam Drugs and Organics Ltd
MANKIND
Mankind Pharma Ltd
MARKSANS
Marksans Pharma Ltd
MEDICAMEQ
Medicamen Biotech Ltd
MEDICO
Medico Remedies Ltd
MOREPENLAB
Morepen Laboratories Ltd
NATCOPHARM
Natco Pharma Ltd
NECLIFE
Nectar Lifescience Ltd
NEULANDLAB
Neuland Laboratories Ltd
NGLFINE
NGL Fine Chem Ltd
ONESOURCE
OneSource Specialty Pharma Ltd
ORCHPHARMA
Orchid Pharma Ltd
ORTINGLOBE
Ortin Global Ltd
PANACEABIO
Panacea Biotec Ltd
PFIZER
Pfizer Ltd
PGHL
Procter & Gamble Health Ltd
PPLPHARMA
Piramal Pharma Ltd
RPGLIFE
RPG Life Sciences Ltd
SAILIFE
Sai Life Sciences Ltd
SANOFI
Sanofi India Ltd
SANOFICONR
Sanofi Consumer Healthcare India Ltd
SENORES
Senores Pharmaceuticals Ltd
SHILPAMED
Shilpa Medicare Ltd
SIGACHI
Sigachi Industries Ltd
SMSPHARMA
SMS Pharmaceuticals Ltd
SOLARA
Solara Active Pharma Sciences Ltd
SPARC
Sun Pharma Advanced Research Company Ltd
STAR
Strides Pharma Science Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
SUPRIYA
Supriya Lifescience Ltd
SYNCOMF
Syncom Formulations (India) Ltd
THEMISMED
Themis Medicare Ltd
TORNTPHARM
Torrent Pharmaceuticals Ltd
UNICHEMLAB
Unichem Laboratories Ltd
VALIANTLAB
Valiant Laboratories Ltd
VENUSREM
Venus Remedies Ltd
VINEETLAB
Vineet Laboratories Ltd
VIYASH
Viyash Scientific Ltd
WANBURY
Wanbury Ltd
WINDLAS
Windlas Biotech Ltd
WOCKPHARMA
Wockhardt Ltd
ZIMLAB
Zim Laboratories Ltd
ZYDUSLIFE
Zydus Lifesciences Ltd
Technicals

Kopran Ltd technical analysis: indicators, pivots and CPR.

Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Kopran Ltd — derived from the live tape, not yesterday's close.

Kopran Ltd last traded at ₹206.27 with an intraday range of ₹194.05–₹219 — live indicator, pivot and CPR signals below.

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Live: ₹206.27
LevelPrice (₹)Distance% Δ
R4268.73+62.46+30.28%
R3243.78+37.51+18.18%
R2231.39+25.12+12.18%
R1218.83+12.56+6.09%
PIVOT206.440.170.08%
CURRENT206.27
S1143.98-62.29-30.20%
S2168.93-37.34-18.10%
S3181.49-24.78-12.01%
S4193.88-12.39-6.01%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 206.36P: 206.44TC: 206.53
R1
R2
R3
R4
indicator
LTP: 206.27
PDH: 202.80
PDL: 191.50
● Market Sentiment

KOPRAN is trading Below CPR, indicating Bearishness

● CPR Width

CPR is Narrower, suggesting likely for trending moves

● Opening Range

Day's range: ~

● Price Position

Trading Above opening range, showing Bullishness

Delivery & Volume

Kopran Ltd delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for Kopran Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in Kopran Ltd stood at 27.3% of traded volume, against a 20-day average of 39.8%.

Avg Delivery (20D)39.8%-12.5 ppt latest vs avg
Highest Delivery54.2%on 04 May
Avg Volume (20D)16.36 L20-day run-rate
Conviction Trend↓ Weakening-12.5 ppt latest read
Volume & Delivery · last 20 sessions
Filings & Concalls

Kopran announcements: results, concalls, ratings, M&A.

Filings Kopran sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

Insider Activity

Kopran insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in Kopran as reported to SEBI — buying and selling signals from the people who know the business best.

Kopran insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
Mridula SomaniInsider18 Dec 2024buy+17.65 L
Mridula SomaniInsider18 Dec 2024buy+17.65 L
Corporate Actions

Kopran dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue Kopran has declared, sequenced by announce and record date.

Kopran corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

About the Company

About Kopran Ltd: business, sector, key facts.

What Kopran Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

Kopran Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: KOPRAN, BSE: 524280.

KOPRAN
Pharmaceuticals

Kopran Ltd

NSE · KOPRAN·BSE · 524280·www.kopran.com

Kopran Limited is an integrated pharmaceutical company with a long history, established in 1958 and headquartered in Mumbai, India. Its core business revolves around the manufacturing and marketing of both Active Pharmaceutical Ingredients (APIs) and finished dosage forms of pharmaceuticals. This encompasses a broad range of products distributed both domestically within India and internationally.

The company's product portfolio is extensive and diverse, covering numerous therapeutic categories. Their finished dosage forms include a variety of common pharmaceutical presentations such as tablets, capsules, syrups, dry powders, suspensions, and injectables. These forms are utilized to deliver medications across a wide spectrum of therapeutic areas.

Kopran offers both branded and generic formulations of drugs. The therapeutic areas covered by their products are substantial, including but not limited to: macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, anti-acne medications, anti-infectives, anti-thrombotics, antidiabetics, pain management medications, neuromodulators, gastroenterology drugs, and cardiovascular medications. Furthermore, their offerings extend to drugs for erectile dysfunction, antiallergics, respiratory medications, oncology drugs, central nervous system medications, antiprotozoals, anthelmintics, antipeptic ulcer and gut medications, and various other therapeutic categories.

In summary, Kopran Limited operates as a fully integrated pharmaceutical company, encompassing API production and the manufacturing and marketing of a wide range of finished dosage forms across numerous therapeutic areas. Their long history and diverse product portfolio establish them as a significant player in the Indian and international pharmaceutical markets.

company facts
Founded / IPO17/11/1992
Employees842
SectorHealth Care
HeadquartersMumbai, MAHARASHTRA, IN
Market Cap₹876.34 Cr
Listed OnNATIONAL STOCK EXCHANGE OF INDIA
leadership11 on record
Shri. Susheel Somani
Non-Executive Chairman of the Board
Shri. Surendra Somani
Executive Vice Chairman of the Board
Mr. Basant Soni
Chief Financial Officer
Mr. Sunil Sodhani
Compliance Officer, Company Secretary
Mr. Adarsh Somani
Additional Non-Executive Director
Mr. Varun Somani
Additional Non-Executive Director
Mr. Narayan Atal
Non-Executive Independent Director
Dr. Sunita Banerji
Non-Executive Independent Director
Mrs. Mamta Biyani
Non-Executive Independent Director
Dr. Siddhan Subramanian
Non-Executive Independent Director
Ms. Chandni Shah
Investor Relations
§ ∞ · Plainly Answered

Questions investors ask about Kopran Ltd (KOPRAN).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of Kopran Ltd (KOPRAN)?

The current share price of Kopran Ltd (KOPRAN) is ₹206.27. Today, the stock has gained by ₹12.69 (6.56%), trading in a range of ₹194.05 to ₹219. The stock opened at ₹194.5 with a trading volume of 38,54,785 shares.

02Is Kopran Ltd stock a good investment for long-term?

Kopran Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹876.34 crores, P/E ratio of 38.72, ROE of -0.05%, and ROCE of 9.75%. The dividend yield stands at 2.26%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of Kopran Ltd stock?

The 52-week high price of Kopran Ltd (KOPRAN) is ₹219, while the 52-week low is ₹107. Currently trading at ₹206.27, the stock is 88.6% away from its 52-week low and 5.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy Kopran Ltd stock at the current price?

Whether to buy Kopran Ltd stock at ₹206.27 depends on multiple factors. The stock is currently trading with a P/E ratio of 38.72 and P/B ratio of N/A. Today's performance shows a gain of 6.56%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of Kopran Ltd and when is the next dividend?

Kopran Ltd offers a dividend yield of 2.26%, which means for every ₹100 invested at the current price of ₹206.27, you can expect to receive approximately ₹2.26 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of Kopran Ltd?

Kopran Ltd's key financial metrics include: P/E Ratio: 38.72, P/B Ratio: N/A, ROE: -0.05%, ROCE: 9.75%, Dividend Yield: 2.26%, EPS: ₹3.41, Book Value: ₹107.35, Debt-to-Equity: 0.29, and Current Ratio: N/A. The company's market cap stands at ₹876.34 crores. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is Kopran Ltd stock performing today in the market?

Kopran Ltd stock opened at ₹194.5 and is currently trading at ₹206.27, showing a gain of ₹12.69 (6.56%). The intraday high is ₹219 and low is ₹194.05. The trading volume stands at 38,54,785 shares, indicating strong market participation today.

08What is the P/E ratio of Kopran Ltd and what does it indicate?

Kopran Ltd has a Price-to-Earnings (P/E) ratio of 38.72, which means investors are willing to pay ₹38.72 for every ₹1 of earnings. With an EPS of ₹3.41, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about Kopran Ltd (KOPRAN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.